Dr. Julian Rees is a co-founder of HOPO Therapeutics and has served as its President and Chief Executive Officer since incorporation in 2020. He has over a decade of research experience studying the interactions between metal ions and biological systems, with foci in biological inorganic chemistry, ligand and chelator design, and f-block element decorporation. Dr. Rees has authored and designed multiple research studies detailing critical investigations of the efficacy and applications of HOPO’s lead drug candidate. He received a B.A. in Chemistry from Goucher College, was a DAAD Graduate Scholar at the Max Planck Institute for Chemical Energy Conversion, earned his M.S. and Ph.D. in Chemistry from the University of Washington, and completed a Postdoctoral Fellowship at Lawrence Berkeley National Laboratory. In addition to his role at HOPO Therapeutics, Dr. Rees is also adjunct faculty in chemistry at Berkeley City College.